MediGene AG to Present at the 11th Annual Biotechnology Industry Organization (BIO) CEO & Investor Conference in New York

Martinsried/Munich, February 6, 2009. The biotech company MediGene AG (Frankfurt, Prime Standard: MDG) will present at the 11th Annual BIO CEO & Investor Conference at the Hotel Waldorf-Astoria in New York City. The speech will be given by Dr. Peter Heinrich, Chief Executive Officer of MediGene AG, on February 9, 2009 at 11:00 a.m. local time (17:00 CET). Dr. Heinrich will give a business summary and update the audience on the latest business developments. The presentation will be webcast on the internet and will be available from February 9 at www.medigene.com.

MediGene is the first German biotech company to have drugs on the market, which are being distributed by partner companies. MediGene has several drug candidates in clinical development, including EndoTAG(TM)-1 which could offer substantial sales returns. In addition, the company has numerous projects in research and pre-clinical development and possesses innovative platform technologies. MediGene focuses on the research and development of novel drugs for the treatment of cancer and autoimmune diseases.

This press release contains forward-looking statements representing the opinion of MediGene as of the date of this release. The actual results achieved by MediGene may differ significantly from the statements made herein. MediGene is not bound to update any of these forward-looking statements. EndoTAG(TM) and MediGene® are trademarks of MediGene AG, This trademark may be owned or licensed in selected locations only.

MediGene AG is a publicly listed (Frankfurt, Prime Standard: MDG) biotechnology company located in Martinsried/Munich, Germany, with subsidiaries in Oxford, UK and San Diego, USA.